BridgeBio Pharma, Inc.
BBIONASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $13.42B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $52.75$93.42
- Volume (live)
- -
- Avg. volume (3M)
- 2.92M
BridgeBio Pharma (BBIO) Stock Price & Financial Analysis
BridgeBio Pharma Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $67.02 - $68.86 |
|---|---|
| 52-Week High | $93.42 |
| 52-Week Low | $52.75 |
| Open | $67.69 |
| Volume (last close) | 2.40M |
| Average Volume (3M) | 2.92M |
| Revenue (TTM) | 713.07M |
|---|---|
| Net Income (TTM) | -691.87M |
| Free Cash Flow (TTM) | -439.89M |
| EPS (TTM) | −$3.57 |
| Profit Margin | -97.03% |
| Operating Margin | -67.01% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 13.42B |
|---|---|
| Shares Outstanding | 195.79M |
| Price to Sales (P/S) | 18.82 |
| Price to Book (P/B) | -5.36 |
| EV/EBITDA | -30.75 |
| 50-Day MA | $72.27 |
|---|---|
| 200-Day MA | $72.98 |
| 1-Year Change | +26.59% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
BridgeBio Pharma at a Glance
As of the Oct 23, 2026 close, BridgeBio Pharma (BBIO) has a market capitalization of $13.42B. The stock trades at 18.8× sales. Over the trailing twelve months it lost $691.87M on revenue of $713.07M and burned $439.89M of free cash flow. Revenue grew 202.4% year over year.
As of its latest reported balance sheet, it holds $677.91M in cash and securities against $2.49B of debt, a net debt position of $1.82B.
BridgeBio Pharma does not currently pay a dividend.
The share price is up 26.6% over the past year. At $68.56 (the Oct 23, 2026 close) it sits within its 52-week range of $52.75 to $93.42, below its 200-day moving average of $72.98.
Based on 21 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $109.22, 59.3% above the Oct 23, 2026 close.
Frequently Asked Questions About BridgeBio Pharma
What is the current stock price for BBIO?
As of the Oct 23, 2026 close, BBIO stock trades at $68.56. The 52-week range is $52.75–$93.42, with a day range of $67.02–$68.86.
What is the P/E ratio for BBIO?
The P/E ratio (Price-to-Earnings) for BBIO is shown in the Key Statistics section. This valuation metric helps compare BridgeBio Pharma, Inc. to industry peers.
Does BBIO pay dividends?
BridgeBio Pharma does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for BBIO?
Based on ratings from 21 professional analysts over the last 90 days, the consensus for BBIO is Buy. The average 12-month price target is $109.22, a 59.3% upside from the Oct 23, 2026 close of $68.56.
What is the market cap of BBIO?
As of the Oct 23, 2026 close, BridgeBio Pharma's market capitalization is $13.42B, classifying it as a large-cap company. BridgeBio Pharma operates in the Healthcare sector within the Biotechnology industry.